Companies Plan to Explore Broad Therapeutic Potential of AIM Class

14-12-2011

Abbott and Reata Pharmaceuticals announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators (AIMs). The agreement is in addition to the partnership between the two ...

more

Pivotal clinical trial will further assess drug candidate's effect on kidney function

20-06-2011

Reata Pharmaceuticals, Inc. and Abbott announced the initiation of a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease (eGFR of 15-29 mL/min/1.73 m2) and type 2 diabetes.The trial, known as BEACON (Bardoxolone ...

more

Results Suggest Bardoxolone Methyl May Reduce the Stage of Disease and Improve Measures of Kidney Function in Patients with Chronic Kidney Disease and Type 2 Diabetes

22-11-2010

Reata Pharmaceuticals and Abbott announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney ...

more

27-09-2010

Abbott and Reata Pharmaceuticals announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late Phase 2 trials for the treatment of chronic kidney disease (CKD). Under terms of the agreement, Reata ...

more